- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
14 result(s) found for: Keratinocyte.
Displaying page 1 of 1.
EudraCT Number: 2010-021186-70 | Sponsor Protocol Number: 10089DMCA-CS | Start Date*: 2010-10-01 |
Sponsor Name:Belfast Health and Social Care Trust | ||
Full Title: Keratinocyte growth factor in Acute lung injury to REduce pulmonary dysfunction – a randomised placebo controlled trial (KARE) | ||
Medical condition: Acute Lung Injury | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-003212-22 | Sponsor Protocol Number: 10MI30 | Start Date*: 2013-06-03 | |||||||||||
Sponsor Name:GOSH/ICH Joint Research & Development Office | |||||||||||||
Full Title: Phase I study of ex-vivo lentiviral gene therapy for the inherited skin disease Netherton Syndrome | |||||||||||||
Medical condition: Netherton Syndrome (NS) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000441-58 | Sponsor Protocol Number: 08005DM-A | Start Date*: 2009-01-22 |
Sponsor Name:Belfast City Hospital | ||
Full Title: Investigation of the protective effects of keratinocyte growth factor (KGF) in a human lipopolysaccharide induced model of acute lung injury | ||
Medical condition: Acute lung injury | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004616-31 | Sponsor Protocol Number: FR1 | Start Date*: 2008-04-11 | |||||||||||
Sponsor Name:Universitair Medisch Cemtrum Utrecht | |||||||||||||
Full Title: Prevention of neutrophil induced extracellular matrix damage following skin exposure to solar simulating radiation (SSR) | |||||||||||||
Medical condition: sunburn (erythema solaris), photoaging (elastosis solaris) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003895-15 | Sponsor Protocol Number: 82720 | Start Date*: 2022-02-23 | ||||||||||||||||
Sponsor Name:Bispebjerg Hospital, Department of Dermatology and Venereology | ||||||||||||||||||
Full Title: Impact of human papillomavirus (HPV) vaccination on burden of disease in patients with actinic keratosis ― a double-blind randomized controlled trial | ||||||||||||||||||
Medical condition: Actinic Keratosis (AK) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012717-22 | Sponsor Protocol Number: UCL/08/0167 | Start Date*: 2010-01-13 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: UKALL14 - A randomized trial for adults with newly diagnosed acute lymphoblastic leukemia | |||||||||||||
Medical condition: Acute Lymphoblastic Leukemia (ALL) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002016-28 | Sponsor Protocol Number: 20040118 | Start Date*: 2005-01-04 | |||||||||||
Sponsor Name:Amgen | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduct... | |||||||||||||
Medical condition: Oral mucositis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) AT (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000213-35 | Sponsor Protocol Number: 20020402 | Start Date*: 2005-08-05 | |||||||||||
Sponsor Name:Swedish Orphan Biovitrum AB (publ.) | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduct... | |||||||||||||
Medical condition: Oral mucositis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) AT (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005007-14 | Sponsor Protocol Number: 20040122 | Start Date*: 2005-05-20 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) for Reduction of Oral Mucositis in Subjects Wit... | |||||||||||||
Medical condition: Oral Mucositis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003050-24 | Sponsor Protocol Number: B7931022 | Start Date*: 2019-08-02 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06700841 CREAM APPLIED ONCE OR T... | |||||||||||||
Medical condition: Atopic Dermatitis (AD) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) DE (Completed) HU (Completed) BG (Completed) PL (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000211-24 | Sponsor Protocol Number: IMAT-PV | Start Date*: 2013-10-01 | |||||||||||
Sponsor Name:Ruprecht-Karls-University Heidelberg | |||||||||||||
Full Title: A multicenter, randomized, placebo-controlled, double-blind proof of concept study to evaluate the efficacy and safety of the human normal immunoglobulin Intratect® 5% for intravenous use as adjuva... | |||||||||||||
Medical condition: patients with Pemphigus vulgaris | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001716-31 | Sponsor Protocol Number: 20040124 | Start Date*: 2015-09-17 | |||||||||||
Sponsor Name:Swedish Orphan Biovitrum AB (publ.) | |||||||||||||
Full Title: A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduct... | |||||||||||||
Medical condition: Oral Mucositis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-003116-33 | Sponsor Protocol Number: 20030185 | Start Date*: 2005-04-11 | |||||||||||
Sponsor Name:Swedish Orphan Biovitrum (Sobi) AB (publ) | |||||||||||||
Full Title: A Phase 2 Study to Evaluate the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) in the Reduction of Dysphagia in Patients Receiving Concurrent Chemoradiotherapy fo... | |||||||||||||
Medical condition: Dysphasia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005606-30 | Sponsor Protocol Number: CAM-THY | Start Date*: 2012-04-25 | |||||||||||||||||||||||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge | |||||||||||||||||||||||||||||||||
Full Title: Keratinocyte Growth Factor - promoting thymic reconstitution and preventing autoimmunity after alemtuzumab (Campath-1H) treatment of multiple sclerosis. CAM-THY | |||||||||||||||||||||||||||||||||
Medical condition: This trial will test the efficacy of Kepivance in the prevention of new autoimmune diseases in patients who have multiple sclerosis (MS)who are being treated with alemtuzumab. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.